Psoriasis: guselkumab tops ustekinumab in indirect comparison

  • Diels J & al.
  • Br J Dermatol
  • 25 Oct 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Guselkumab is associated with better long-term efficacy compared with ustekinumab for patients with moderate to severe psoriasis, according to an indirect comparison using pooled analysis of individual patient data from the VOYAGE 1/2 and NAVIAGATE trials.

Why this matters

  • There have been no head-to-head comparisons of guselkumab and ustekinumab, necessitating this type of indirect comparison.

Key results

  • Guselkumab was associated with a higher probability of achieving ≥90% reduction in the Psoriasis Area and Severity Index (PASI 90) compared with ustekinumab at week 40 (74.2% vs 54.5% [OR, 2.40; 95% CI, 1.89-3.13]).
  • At 40 weeks, guselkumab was also associated with higher probability of achieving PASI 75 (87.8% vs 77.1% [OR, 2.14; 95% CI, 1.54-2.94]) and PASI 100 (49.7% vs 28.1% [OR, 2.53; 95% CI, 2.00-3.23]) compared with ustekinumab.

Study design

  • 825 patients from the VOYAGE 1/2 trials and 853 patients from the NAVIGATE trial were included in the analysis.
  • Funding: Janssen Inc.

Limitations

  • Indirect comparisons between trials with different settings may have introduced confounding factors and bias.